Cargando…
Bivalirudin in Patients Undergoing PCI: State of Art and Future Perspectives.
Acute coronary syndrome (ACS) represents the most common cause of death worldwide. Percutaneous coronary intervention (PCI) is the management of choice in patients with ACS and occurrence of intra-procedural thrombotic complications are an independent predictor of mortality and other major adverse c...
Autores principales: | Galasso, G, Mirra, M, De Luca, G, Piscione, F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università di Salerno
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4912339/ https://www.ncbi.nlm.nih.gov/pubmed/27326396 |
Ejemplares similares
-
Bivalirudin versus heparin in primary PCI: clinical outcomes and cost analysis
por: Deharo, Pierre, et al.
Publicado: (2018) -
Safety and Efficacy of Bivalirudin versus Unfractionated Heparin Monotherapy in Patients with CAD and DM Undergoing PCI: A Retrospective Observational Study
por: Li, Jing, et al.
Publicado: (2022) -
Safety of Bivalirudin Combined with Ticagrelor in the Emergency PCI in Patients with Acute ST-Segment Elevation Myocardial Infarction
por: Wang, Zheng-Dong, et al.
Publicado: (2022) -
Management of Atrial Fibrillation in Patients Undergoing Percutaneous Coronary Intervention
por: Mirra, M, et al.
Publicado: (2014) -
Bivalirudin in percutaneous coronary intervention
por: Lehman, Sam J, et al.
Publicado: (2006)